Investor
The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.
The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
Last week, the wearables company announced it opened an investigation into apparent manipulation in trading its common shares following a 1-for-15 reverse stock split.
The investigation follows shareholder approval of a 1-for-15 reverse stock that took effect earlier this week.
Vineeta Agarwala, general partner at Andreessen Horowitz (a16z) Bio + Health, sat down with MobiHealthNews to discuss knownwell's expansion into Texas.
The employer-focused hybrid care provider will use the funds to scale its operations and expand access to its preventative care model.
The company will use the funds to scale its operations and further develop its technology as it aims to establish gait monitoring as a mainstream tool.
The company's Synapsis AI platform automates complex data readings, which allows for more efficient and optimal clinical research.
The funding includes $4.5 billion for the firm's core VC funds, $1.5 billion for its Creation strategy and $2 billion for separately managed accounts.